Amniotics AB (publ)

https://www.amniotics.com

LinkedIn: https://www.linkedin.com/company/amniotics

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics also has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs. Amniotics (publ) has it´s headquarter in Lund, Sweden. Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90. The company is listed at Nasdaq First North Growth Market in Stockholm. *

	Start	2022-01-20 existent
	Industry	stem cell therapy
	Person	Engklide, Kåre (Amniotics 202201 CEO)

	Region	Lund
	Country	Sweden
	Street	2 Scheelevägen Medicon Village
	City	22363 Lund
		Address record changed: 2022-01-27

Basic data	Employees	n. a.

		* Document for »About Section«: Amniotics AB. (1/20/22). "Press Release: Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies".

		Record changed: 2024-02-12

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Amniotics AB (publ)

[1] Amniotics AB. (1/20/22). "Press Release: Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)